Drugs / Irinotecan liposome
Irinotecan liposome
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06766266 | Jan → Apr 2025 overdue | non-invasive bladder urothelial carcinoma | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06513455 | Sep 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06341309 | Aug 2024 → Apr 2026 overdue | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT07646717 | Feb 2026 → Dec 2027 expected | intrahepatic cholangiocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07395063 | Feb 2026 → Feb 2029 expected | colorectal cancer | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07070479 | Jun 2025 → Jan 2027 expected | nasopharyngeal carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 2 | NCT06700603 | Nov 2024 → Dec 2025 overdue | malignant pancreatic neoplasm | Rui-hua Xu, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06699459 | Nov 2024 → Nov 2026 expected | biliary tract cancer | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06478043 | Oct 2024 | small cell lung carcinoma | Zhejiang Cancer Hospital | Completed | No outcome recorded |
| Phase 2 | NCT06475326 | Jun 2024 → Jun 2025 overdue | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05969899 | Jul 2023 → Jul 2025 overdue | colorectal cancer | Fudan University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03732508 | Nov 2018 → Nov 2019 | esophageal squamous cell carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07309289 | Jul 2025 → Mar 2029 expected | colorectal cancer | Shanghai Zhongshan Hospital | Recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06578052 | Aug 2024 → Sep 2027 expected | malignant pancreatic neoplasm | Junjie Hang | Recruiting | No outcome recorded |
| — | NCT06258642 | Apr 2024 → Apr 2026 overdue | small cell lung carcinoma | Fudan University | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06531278 Background | Jul 2024 → Dec 2026 expected | digestive system carcinoma | Jiang Long | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Irinotecan Liposome | “Drug: Irinotecan Liposome Irinotecan liposome injection will be administered by an intravenous infusion at the dose of 50 mg/m\^2, d1, 14 days per cycle.” NCT07309289 ↗15“irinotecan liposome 60 mg/m2, iv, for at least 90 minutes” NCT05969899 ↗ |
| Known as | HR070803 | “Jiangsu Hengrui Pharmaceutical Co., Ltd. developed irinotecan hydrochloride liposome injection (HR070803) has both protection Protective, long-term cyclic and passively targeted.” NCT06531278 ↗ |
| Known as | irinotecan hydrochloride liposome injection | “Jiangsu Hengrui Pharmaceutical Co., Ltd. developed irinotecan hydrochloride liposome injection (HR070803) has both protection Protective, long-term cyclic and passively targeted.” NCT06531278 ↗ |
| Known as | Nal-IRI | “Irinotecan liposome (Nal-IRI) in combination with 5-FU/sodium levofolinate” NCT06700603 ↗ |
| Route | Intravenous | “Irinotecan liposome intravenous infusion will be administered during the first day of treatment.” NCT03732508 ↗ |